R&D Sector Under Threat?

To read the full article, please sign in or take a free trial.

The UK government's renegotiation of the Pharmaceutical Price Regulation Scheme (PPRS), which sets the prices for drugs paid by the National Health Service, is threatening the competitiveness of the country's R&D sector, claims the Association of the British Pharmaceutical Industry (ABPI).